EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

Comparative Effectiveness and Safety of PI‐Rd Triplets in Relapsed/Refractory Multiple Myeloma: INSIGHT‐MM Data Analysis

Noemi Puig iD, Xavier Leleu iD, Hans C Lee, Faith E Davies, Roman Hájek, Vania Hungria, Michael A Thompson, Gordon Cook, Jorge Vela Ojeda, Katja C Weisel iD, Jesus G Berdeja, Saad Z Usmani und 7 weitere

European Journal of Haematology · 2026

DOI: 10.1111/ejh.70079 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Journal of Haematology, 2026. Verfasst von Noemi Puig und 18 weiteren Autor:innen. Beteiligte Einrichtung: University Hospital of Salamanca, Salamanca, Spain. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Multiple Myeloma, Proteasome Inhibitors. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Takeda Development Center Americas Inc. (TDCA), Takeda Development Center Americas.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To assess the effectiveness/safety of three proteasome inhibitors (PIs), plus lenalidomide‐dexamethasone (Rd) triplet regimens, for the treatment of relapsed/refractory multiple myeloma (RRMM) in a real‐world setting, using data from the observational INSIGHT‐MM study (NCT02761187).

Methods

Adults with RRMM who received ixazomib, carfilzomib, or bortezomib plus Rd (IRd, KRd, or VRd, respectively) in the second or later line of therapy (LoT) were included. Patient characteristics, response to therapy (Kaplan–Meier analysis), and safety were reported descriptively. Multivariable Cox proportional hazards models were used to assess comparative effectiveness between regimens, whilst adjusting for cohort imbalances.

Results

Overall, 356 LoTs (IRd n = 181; KRd n = 96; VRd n = 79) from 348 patients were included. There was heterogeneity in patient characteristics between cohorts. Median real‐world progression‐free survival (rwPFS) for IRd, KRd, and VRd was 14.5, 13.2, and 9.1 months, respectively. After adjustment for baseline covariates, no significant differences in rwPFS were observed between regimens. All three regimens demonstrated a manageable safety profile.

Conclusions

IRd, KRd, and VRd demonstrated comparable effectiveness and safety for the treatment of RRMM in a real‐world setting, highlighting the need for a holistic evaluation of individual patients' needs and circumstances when selecting an appropriate PI. Clinical Registration Clinical trial registration for the INSIGHT‐MM study: NCT02761187; https://clinicaltrials.gov/study/NCT02761187

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsMultiple MyelomaProteasome InhibitorsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedDexamethasoneDrug Resistance, NeoplasmLenalidomideRecurrenceTreatment Outcome

Stichwörter der Autor:innen

comparative effectiveness researchholistic healthmultiple myelomapragmatic clinical trialsprogression‐free survivalproteasome inhibitorssafety

Substanzen

DexamethasoneLenalidomideProteasome Inhibitors

Autor:innen und Institutionen

  • University Hospital of Salamanca, Salamanca, Spain.
  • CHU Poitiers, Poitiers, France.
  • University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • NYU Langone, New York, New York, USA.
  • Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic.
  • Department of Haematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.

ORCID-Profile: Noemi Puig, Xavier Leleu, Katja C Weisel, Argiris Symeonidis

Förderung

  • NCI NIH HHS
  • Takeda Development Center Americas Inc. (TDCA)
  • Takeda Development Center Americas

Zitieren

APA

Puig, N., Leleu, X., Lee, H. C., Davies, F. E., Hájek, R., Hungria, V., Thompson, M. A., Cook, G., Ojeda, J. V., Weisel, K. C., Berdeja, J. G., Usmani, S. Z., Symeonidis, A., Nascimento-Ferreira, I., Arthur, D., Mokrá, L., Ren, K., Cherepanov, D., & Terpos, E. (2026). Comparative Effectiveness and Safety of PI‐Rd Triplets in Relapsed/Refractory Multiple Myeloma: INSIGHT‐MM Data Analysis. European Journal of Haematology. https://doi.org/10.1111/ejh.70079

Vancouver

Puig N, Leleu X, Lee HC, Davies FE, Hájek R, Hungria V, et al. Comparative Effectiveness and Safety of PI‐Rd Triplets in Relapsed/Refractory Multiple Myeloma: INSIGHT‐MM Data Analysis. European Journal of Haematology. 2026. doi:10.1111/ejh.70079

BibTeX
@article{Puig2026,
  author = {Puig, Noemi and Leleu, Xavier and Lee, Hans C and Davies, Faith E and Hájek, Roman and Hungria, Vania and Thompson, Michael A and Cook, Gordon and Ojeda, Jorge Vela and Weisel, Katja C and Berdeja, Jesus G and Usmani, Saad Z and Symeonidis, Argiris and Nascimento-Ferreira, Isabel and Arthur, David and Mokrá, Lenka and Ren, Kaili and Cherepanov, Dasha and Terpos, Evangelos},
  title = {Comparative Effectiveness and Safety of PI‐Rd Triplets in Relapsed/Refractory Multiple Myeloma: INSIGHT‐MM Data Analysis},
  journal = {European Journal of Haematology},
  year = {2026},
  doi = {10.1111/ejh.70079}
}
Kostenlos starten →